MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

Northern Tool + Equipment is bringing the high-octane excitement of Monster Jam® to the Little Rock community. On Thursday, February 20, customers will have the chance to experience the thrill-seeking ...

PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment ... 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc ...

One milliliter of culture was added to 100 mL of LB with 30 μg/mL kanamycin monosulfate and incubated at 37°C and 160 r/min until the OD 600 reached 0.4–0.6. Expression was induced with 0.1 mM ...

New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...

Gradients to optimize applications. Fast determination of thiosulfate, thiocyanate, and perchlorate. Can be used with instruments from third party manufacturers as well. Offer a wide choice of ...

Although many of these compounds are yet to be evaluated in clinical trials, the recent FDA approval of sodium thiosulfate for the treatment of cisplatin-induced hearing loss in pediatric patients ...